ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

Reduced-Dose Glucocorticoids for GPA & Microscopic Polyangiitis

Arthritis & Rheumatology  |  December 1, 2023

SAN DIEGO—In a study titled Real-Life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis, Nagle et al. evaluated the efficacy and safety of the reduced-dose glucocorticoid regimen in a real-world setting. Background/Purpose Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with…

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAVAAV FocusRheumACR Convergence 2023Arthritis & RheumatologyCorticosteroidsgranulamatosis with polyangiitismicroscopic polyangiitis (MPA)Research

Top Research in ANCA-Associated Vasculitis Presented at ACR Convergence 2023

Philip Seo, MD, MHS  |  November 21, 2023

SAN DIEGO—Vasculitis expert and former editor of The Rheumatologist, Dr. Philip Seo gives us his picks for the 10 most important abstracts in ANCA-associated vasculitis to come out of ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAVAAV FocusRheumACR Convergence 2023

The Eyes Have It

Jason Liebowitz, MD, FACR  |  November 14, 2023

SAN DIEGO—Many rheumatologists see patients referred for uveitis, and Laura Kopplin, MD, PhD, assistant professor of ophthalmology and visual sciences, University of Wisconsin, Madison, discussed inflammatory disease of the eye at ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:ACR Convergence 2023panuveitisUveitis

Updates in Vasculitis Criteria, Guidelines & Medications

Jason Liebowitz, MD, FACR  |  November 10, 2023

BALTIMORE—2022 was an exciting year in the field of vasculitis, not least of all because the ACR and EULAR released classification criteria for several forms. This development came just one year after the release of ACR/Vasculitis Foundation (VF) guidelines on the management of a number of vasculitides. With so much new information to be absorbed,…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceVasculitis Tagged with:ANCA-Associated Vasculitiseosinophilic granulomatosis with polyangiitis (EGPA)Glucocorticoidsgranulomatosis with polyangiitismicroscopic polyangiitis (MPA)VEXAS

Octagam Trial Results Show Promise

Thomas R. Collins  |  November 9, 2023

Since the New England Journal of Medicine publication on intravenous immune globulin (IVIG) for dermatomyositis late last year, the data have proved a major lift for patient care, offering crucial new insights into how best to manage patients and clues about how to minimize risks.1 The ProDERM trial results also seem to have opened up…

Filed under:ConditionsDrug UpdatesMyositis Tagged with:dermatomyositisintravenous immune globulinOctagam

What’s New in RA Research?

Jason Liebowitz, MD, FACR  |  November 8, 2023

Dr. Aletaha discussed several studies of interventions in pre-RA, including SAVE, STIVEA, PROMPT, PRAIRI, TREAT EARLIER and STOP-RA.

Filed under:EULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:RA Resource CenterRheumatoid Arthritis (RA)

All That Is Old—& New: Treatment Implications for Rheumatoid Arthritis

Jason Liebowitz, MD, FACR  |  November 7, 2023

EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…

Filed under:Meeting ReportsRheumatoid Arthritis Tagged with:EULAR 2023RA Resource CenterRheumatoid Arthritis (RA)

Glucocorticoids in RA

David S. Pisetsky, MD, PhD  |  November 7, 2023

The historical & continuing roles of glucocorticoids in the treatment of RA are discussed. 

Filed under:Education & TrainingRheumatoid Arthritis Tagged with:GlucocorticoidsRA Resource CenterRheumatoid Arthritis (RA)

Criteria, Guidelines & Medications: Updates in the World of Vasculitis

Jason Liebowitz, MD, FACR  |  November 1, 2023

The 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of Rheumatic Diseases Symposium session titled, Updates on Vasculitis provided an overview of the latest information on vasculitis diagnosis and treatment.

Filed under:ConditionsMeeting ReportsVasculitis Tagged with:ANCA-Associated VasculitisEGPAGPAmicroscopic polyangiitis (MPA)

RheumMadness 2023: The Results Are In

David L. Leverenz, MD, MEd  |  September 11, 2023

RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…

Filed under:Career DevelopmentConditionsEducation & TrainingProfessional TopicsResearch RheumRheumatoid ArthritisVasculitis Tagged with:AAV FocusRheumANCA-Associated VasculitisAntibodiescyclophosphamideetanerceptFellowsFellows-in-TrainingGlucocorticoidsonline educationpreclinicalprednisoneRheumatology Research FoundationRheumMadnessrituximabTNF-Alpha inhibitor

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 47
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences